Amlexanox

DRUG3 trials

Sponsors

Access Pharmaceuticals, Inc., University of Michigan

Conditions

Diabetes Mellitus Type 2Non Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver DiseaseObesityOral Mucositis

Phase 2

Study to Determine the Effects Treatment With Amlexanox 0.5% Oral Rinse Solution on Oral Mucositis Associated With Radiation Therapy for Cancer of the Head and Neck Region

CompletedNCT01083875

Access Pharmaceuticals, Inc.Oral Mucositis

Start: 2000-02-29End: 2001-06-30Updated: 2010-03-18

Amlexanox for Type 2 Diabetes and Obesity

TerminatedNCT01842282

University of MichiganDiabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity

Start: 2013-07-19End: 2014-02-25Updated: 2024-05-07

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

CompletedNCT01975935

University of MichiganDiabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity

Start: 2014-01-31End: 2017-08-18Updated: 2018-11-07